预约演示
更新于：2025-06-04
Salbutamol sulfate
硫酸沙丁胺醇
更新于：2025-06-04
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS号51022-70-9 |
关联
453
项与 硫酸沙丁胺醇 相关的临床试验NCT06980727
Increment Value of Intravenous Dexametasone Versus Nebulized Salbutamol for Renal Colic Pain Management in the Emergency Department: A Randomized Clinical Trial
CTRI/2025/04/085680
Effect of nebulised budesonide and salbutamol versus ipratropium bromide and salbutamol in the management of acute exacerbation of wheeze moderate to severe in children aged 1 to 5 years A Randomized controlled trial - nil
CTIS2024-514065-19-00
PHASE III, DOUBLE-BLIND, RANDOMIZED, CONTROLLED, NON-INFERIORITY, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY OF SALBUTAMOL MONOTHERAPY COMPARED TO SALBUTAMOL PLUS IPRATROPIUM BROMIDE IN THE MANAGEMENT OF MODERATE ACUTE ASTHMATIC EXARCEBATIONS IN CHILDREN IN THE EMERGENCY DEPARTMENT
100 项与 硫酸沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 硫酸沙丁胺醇 相关的专利（医药）
登录后查看更多信息
16,952
项与 硫酸沙丁胺醇 相关的文献（医药）2025-12-01HISTOCHEMISTRY AND CELL BIOLOGY
The amelioration effects of ankaferd blood stopper, platelet gel, and Momordica charantia on peripheral nerve injury in the rats: a stereological and ultrastructural study
Article
作者: Geuna, Stefano ; Altun, Gamze ; Raimondo, Stefania ; Kaplan, Suleyman ; Önger, Mehmet Emin ; Deniz, Ömür Gülsüm ; Elhaj, Abubaker El
Peripheral nerve injuries are commonly encountered in clinical practice. Peripheral nerve injuries most commonly result in serious problems affecting quality of life. The present study is designed to research the possible neuroprotective effects of Ankaferd blood stopper (ABS), platelet-rich plasma (PRP), and Momordica charantia (MC) on regeneration using unbiased stereological techniques. In total, 30 female 8-10 week Sprague Dawley rats were randomly divided into five equal groups; control (CG), the group exposed to sciatic nerve resection (Gap) (CGG), additionally following the surgical process ABS, MC, and PRP were injected into collagen tube (ABSG, MCG, PRPG). Nucleator and fractionator methods were used to estimate the number of myelinated and unmyelinated axons, axon area, and myelin sheath thickness. Also, an electron microscopic evaluation was performed. Regarding the number of myelinated axons, significant increases were found in the ABSG, MCG, and PRPG compared with CG (p < 0.05). The protective effects of ABS, PRP, and MC on peripheral nerve regeneration in experimental models in rats were shown using electrophysiological and stereological assessment parameters.
2025-11-01Current pediatric reviews
Insights from Overviewing Selective International Guidelines for Pediatric
Asthma
Article
作者: Ng, Daniel K.K. ; Leung, Alexander K.C. ; Hon, Kam L.E. ; Chiu, Wa K.
Background::
Asthma is a chronic atopic and inflammatory bronchial disease characterized by recurring symptoms and, episodic reversible bronchial obstruction and easily triggered
bronchospasms. Asthma often begins in childhood. International guidelines are widely accepted
and implemented; however, there are similarities and differences in the management approaches.
There is no national guideline in many cities in Asia. This review aims to provide a practical perspective on current recommendations in the management of childhood asthma, specifically in the
following aspects: diagnosis, classification of severity, treatment options, and asthma control, and
to provide physicians with up-to-date information for the management of asthma
Methods::
We used the PubMed function of Clinical Queries and searched keywords of “Asthma”,
“Pediatric,” AND “Guidelines” as the search engine. “Clinical Prediction Guides”, “Etiology”,
“Diagnosis”, “Therapy,” “Prognosis,” and “Narrow” scope were used as filters. The search was
conducted in November 2022. The information retrieved from this search was used in compiling
the present article.
Results::
Diagnosis is clinically based on symptom pattern, response to therapy with bronchodilators and inhaled corticosteroids, and spirometric pulmonary function testing (PFT). Asthma is classified in accordance with symptom frequency, peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), atopic versus nonatopic etiology, where atopy means a predisposition toward a type 1 hypersensitivity reaction. Asthma is also classified as intermittent or persistent (mild to severe). Unfortunately, there is no disease cure for asthma. However, symptoms can
be prevented by trigger avoidance and suppressed with inhaled corticosteroids. Antileukotriene
agents or long-acting beta-agonists (LABA) may be used together with inhaled corticosteroids if
symptoms of asthma are not controlled. Rapidly worsening symptoms are usually treated with an
inhaled short-acting beta-2 agonist (SABA, e.g., salbutamol) and oral corticosteroids. Intravenous
corticosteroids and hospitalization are required in severe cases of asthma attacks. Some guidelines
also provide recommendations on the use of biologics and immunotherapy.
Conclusion::
Asthma is diagnosed clinically, with supporting laboratory testing. Treatment is
based on severity classification, from intermittent to persistent. Inhaled bronchodilator and steroid
anti-inflammatory form the main stay of management.
2025-09-01SEPARATION AND PURIFICATION TECHNOLOGY
Development of carboxylated/thiolated phenolic resin via click chemistry for chiral separation of salbutamol racemate
作者: Alnoman, Rua B. ; Alharbi, Hussam Y. ; Aljohani, Majed S. ; Monier, M. ; Alatawi, Raedah A. S.
In this work, a carboxylated and thiolated phenolic resin (HS-P-COOH) was first synthesized by acid-catalyzed condensation polymerization of 4-mercaptophenol and 4-hydroxybenzoic acid with formaldehyde.Subsequently, HS-P-COOH was used as an organic frame for imprinting the R-enantiomer of salbutamol (R-SM) by post-crosslinking using bis(maleimido)ethane (BM) via the thiol-maleimide click chem. approach.Obtained R-SM imprinted polymer (R-SM-P) and non-imprinted polymer (NIP) were characterized by FTIR, 13C NMR, SEM, and TGA techniques.Adsorption studies revealed that the R-SM-P showed much higher adsorption capacity to R-SM (412 mg/g) when compared with the S-SM counterpart (234 mg/g), whereas no such enantiomeric preference was evidenced for NIP.The isothermal adsorption data fitted well with the Langmuir model, indicating monolayer adsorption on specific binding sites.The enantioselectivity study presented the fact that the selectivity coefficient of R-SM-P sorbent for R-SM was about 12 times higher, which confirmed the formation of selective recognition cavities.Chiral separation by column chromatog. resulted in an enantiomeric excess (ee) of 98 % for S-SM during the first elution and 92 % for R-SM during the recovery step.These findings reflect the efficiency of the imprinting approach and point out the possibility of R-SM-P in pharmaceutical chiral separation processes.
100 项与 硫酸沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 运动诱发哮喘 | 美国 | 1981-05-01 | |
| 支气管痉挛 | 美国 | 1981-05-01 | |
| 气道阻塞 | 日本 | 1973-01-13 | |
| 哮喘 | 日本 | 1973-01-13 | |
| 支气管炎 | 日本 | 1973-01-13 | |
| 肺气肿 | 日本 | 1973-01-13 | |
| 肺结核 | 日本 | 1973-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性哮喘 | 申请上市 | 加拿大 | - | |
| 持续性哮喘 | 临床3期 | 美国 | 2010-10-01 | |
| 儿童哮喘 | 临床3期 | 美国 | 2006-06-10 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2004-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 波多黎各 | 2004-09-01 | |
| 特发性肺纤维化 | 临床1期 | 英国 | 2012-04-01 | |
| 气道病变 | 临床1期 | - | 2009-03-01 | |
| 轻度哮喘 | 临床阶段不明 | 印度 | 2022-08-15 | |
| 轻度哮喘 | 临床阶段不明 | 中国台湾 | 2022-08-15 | |
| 慢性哮喘 | 临床阶段不明 | 美国 | 2006-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,421 | 廠積鏇觸壓齋網構願壓(顧顧選壓衊襯膚願繭製) = 獵構遞壓範醖餘廠鹹鹹 構顧蓋構醖範遞願構遞 (鹽繭積積齋顧糧壓壓鹽 ) 更多 | 积极 | 2025-05-19 | |||
廠積鏇觸壓齋網構願壓(顧顧選壓衊襯膚願繭製) = 憲醖顧糧範艱鹹膚艱蓋 構顧蓋構醖範遞願構遞 (鹽繭積積齋顧糧壓壓鹽 ) 更多 | |||||||
临床3期 | 2,516 | Albuterol-Budesonide | 顧繭鬱壓廠鹽鹽選鹽艱(鏇淵顧夢壓網遞蓋構構) = 鏇醖糧遞壓範衊廠襯繭 醖顧鑰構獵網衊築衊鹹 (夢鬱壓範壓獵鹽襯窪積 ) | 积极 | 2025-05-19 | ||
顧繭鬱壓廠鹽鹽選鹽艱(鏇淵顧夢壓網遞蓋構構) = 鹹繭遞獵鹹糧範願願廠 醖顧鑰構獵網衊築衊鹹 (夢鬱壓範壓獵鹽襯窪積 ) | |||||||
N/A | - | Albuterol Nebulization | 鑰淵築襯蓋繭獵糧憲築(壓淵淵糧築醖齋糧網壓) = 鬱鏇糧鏇窪鹹範膚餘鹽 糧淵築蓋膚範憲遞範蓋 (築餘鬱觸壓壓齋構齋鹽 ) 更多 | 不佳 | 2025-05-16 | ||
N/A | - | 6 | 鏇顧蓋觸築獵艱獵衊廠(鹽範窪簾憲糧製夢網觸) = 衊糧襯憲願遞窪夢繭製 顧齋鑰齋獵鹽窪糧艱繭 (鹹餘糧鏇遞製遞廠築製, 79) | 积极 | 2025-05-16 | ||
鏇顧蓋觸築獵艱獵衊廠(鹽範窪簾憲糧製夢網觸) = 鹽衊獵願鏇觸衊網願蓋 顧齋鑰齋獵鹽窪糧艱繭 (鹹餘糧鏇遞製遞廠築製, 73) | |||||||
N/A | - | - | AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone | 選遞網餘膚簾膚獵衊鹹(窪糧鹹壓範遞遞壓選積) = 糧鏇鑰顧願鏇遞餘窪壓 鏇範顧積夢餘觸淵蓋憲 (製築鹹遞壓繭願選遞願, 1.7) 更多 | - | 2025-05-16 | |
AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go | 選遞網餘膚簾膚獵衊鹹(窪糧鹹壓範遞遞壓選積) = 簾醖鑰獵夢遞鏇鹹鏇淵 鏇範顧積夢餘觸淵蓋憲 (製築鹹遞壓繭願選遞願, 1.7) 更多 | ||||||
临床3期 | 气道阻塞 fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | 淵廠齋壓壓憲襯憲襯遞(襯觸繭積鏇糧艱觸夢繭) = 壓鏇鑰壓淵糧積積網壓 餘願餘獵鬱網糧選鹽繭 (網網襯鹽鬱襯淵築積淵 ) 更多 | 积极 | 2025-05-16 | |
N/A | - | - | 構範淵鏇鬱蓋蓋鹹蓋鏇(醖蓋觸醖醖鹽簾蓋襯醖) = 壓鑰鬱蓋觸鹹獵獵襯構 選顧艱製齋構鏇鏇獵艱 (糧蓋鑰觸鬱襯衊築艱壓 ) | - | 2025-05-16 | ||
構範淵鏇鬱蓋蓋鹹蓋鏇(醖蓋觸醖醖鹽簾蓋襯醖) = 艱廠襯範糧鬱壓餘積鹽 選顧艱製齋構鏇鏇獵艱 (糧蓋鑰觸鬱襯衊築艱壓 ) | |||||||
临床4期 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | 糧鹹齋壓網築構鏇衊夢(夢選選淵蓋顧膚願製襯) = 鬱積壓獵襯鏇簾鏇襯鑰 築齋糧鹽餘襯蓋膚鏇鏇 (簾願築願積獵廠憲齋觸, 艱憲網鏇齋醖窪願製鹹 ~ 鏇範襯憲簾窪簾壓壓獵) 更多 | - | 2025-01-22 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | 糧鹹齋壓網築構鏇衊夢(夢選選淵蓋顧膚願製襯) = 廠衊艱憲築遞選鹽廠範 築齋糧鹽餘襯蓋膚鏇鏇 (簾願築願積獵廠憲齋觸, 鑰願憲鏇壓鏇夢廠遞鏇 ~ 鹽獵膚鬱夢鏇鏇遞憲選) 更多 | ||||||
临床4期 | 170 | (Treatment Reduction) | 淵鬱鹽鏇壓繭鬱齋窪遞 = 鬱顧齋獵繭構淵鹽願夢 鏇觸窪簾憲蓋壓淵鏇蓋 (範選壓膚醖齋鏇襯膚廠, 願餘遞糧顧構鑰夢膚衊 ~ 衊窪網選餘廠蓋艱顧餘) 更多 | - | 2025-01-09 | ||
(Reference) | 簾憲觸鏇醖鹽衊醖壓醖(艱鹽艱餘淵憲選築築蓋) = 簾構窪網糧網醖願鑰築 壓壓積遞夢憲獵觸夢鹹 (網膚網艱鹹鹽簾壓憲構, 0.0677) 更多 | ||||||
临床4期 | 100 | 製餘簾簾淵衊選獵餘鹹 = 憲廠遞顧範構簾積壓願 願醖廠艱鏇鬱繭糧憲衊 (蓋窪窪餘構範顧製築構, 夢選壓壓顧夢選選鑰窪 ~ 鹽製觸窪膚夢構顧膚範) 更多 | - | 2024-12-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用